2 Amendments of Bendt BENDTSEN related to 2017/2254(INI)
Amendment 7 #
Draft opinion
Recital A
Recital A
A. whereas antimicrobial resistance (AMR)-related challenges will increase in the years ahead and effective action is reliant on continued, cross-sectoral investments in research & innovation (R&I), including investments in both the public and the private sector, so that better tools, products and approaches can be developed following a One Health approach;
Amendment 47 #
Draft opinion
Paragraph 2
Paragraph 2
2. Calls for incentivisation of the industry, such as the development of various push and pull incentives, to create new medicines and medical devices; believes that incentives are meaningful when they are sustainable over the long term, stimulate investment across the entire product development and life cycle, target key public health priorities, and support appropriate medicinal use;